Upon completion of this session, participants should be able to:

• Review the clinical features and management of patients with specific antibody deficiency and discuss diagnostic strategies with the expanding use of pneumococcal conjugate vaccines.
• Differentiate CVID patients that manifest with immune complications. Describe clinical and immunologic features that can help differentiate complicated from uncomplicated CVID and discuss how this can help guide patient management. How to differentiate the various phenotypes of CVID.
• Characterize common non-infectious manifestations in patients with CVID and review targeted therapeutic strategies to consider.
• Define the non-pharmacological interventions for atopic dermatitis including bathing strategies, emollients, wet wraps, and bleach baths.
• Assess the clinical use and side effects of current topical therapies for atopic dermatitis including TCS, TCI, PDE4 inhibitors, topical JAK-I, and aryl hydrocarbon receptor agonists.
• Summarize the adverse effects of oral and injectable therapies used to treat atopic dermatitis.
• Recognize the different types of insect bites, mite bites, moth bites and more that you might see in the allergy clinic to diagnose and manage appropriately.
• Integrate clinical pearls into the diagnosis of allergic skin conditions in skin of color.
• Analyze clinical pearls in the diagnosis and treatment of prurigo nodularis.
• Evaluate therapies available for CSU, both old and new.
• Review evidence and guidelines for managing mild asthma, including the use of SMART and anti-inflammatory reliever (AIR) strategies, to determine when early anti-inflammatory treatment is indicated and when minimal therapy is sufficient.
• Assess evolving definitions, predictors, and outcomes of asthma remission to guide clinical decision-making and counseling in both pediatric and adult populations.
• Apply a structured, biomarker-informed approach to determine the optimal timing and selection of biologic therapy for patients with uncontrolled asthma.
• Become well versed in practice assessment/quality improvement and diplomate engagement initiatives.
• Gain insight into the deep dive of CAPs first cycles.
• Obtain knowledge on how Diplomates are being acknowledged.
• Apply threshold data to real-world clinical decisions, including risk counseling, introduction vs. avoidance strategies, OIT eligibility, label reading guidance, and emergency preparedness.
• Select appropriate candidates for supervised vs. home oral food challenges, determine optimal timing, prepare families for safe home challenges, and manage common complications or failures and counseling following a food challenge.
• Outline OIT workflows specifically for infants and toddlers, including clinic setup, safety protocols, early-life tolerance considerations, coordination with caregivers, and resource requirements, along with expectations for clinical outcomes.
• Summarize patterns of biologics use in U.S. allergy clinics, including prescribing trends, patient selection criteria, variations in practice, perceived benefits and challenges, and real-world outcomes.
• Explain the evidence supporting the combined use of biologics and OIT, including potential advantages (improved safety, accelerated up-dosing), considerations for timing, monitoring expectations, and identifying candidates who may benefit most.
• Identify the real-world strengths and limitations of SLIT, patient profiles most likely to benefit, how SLIT addresses existing unmet needs, and how it integrates into broader therapeutic strategies.
• Describe the clinical profile of EPIT, including candidate selection, expected benefits, limitations, safety considerations, and how EPIT compares to other available and emerging therapies.
• Share the decision-making process when offering SLIT to an adult patient. Compare indications, efficacy, safety, and practical considerations of sublingual tablets versus drops. Discuss the pros/cons of single-allergen vs multi-allergen SLIT.
• Subcutaneous immunotherapy (SCIT) remains foundational in allergy care. This session highlights 2026 Practice Parameter updates on build-up and maintenance schedules, accelerated protocols, and safety strategies, with practical pearls to optimize SCIT in everyday practice.
• Learn how to consider the risk/benefit ratios of immunotherapy in high-risk patients, including pregnant women, patients with asthma, and patients with other high-risk medical conditions (eg, mastocytosis). Apply current guideline recommendations to guide clinical decision-making.
• Incorporate the latest guideline recommendations and emerging therapies into the management of chronic spontaneous urticaria.
• Assess the evolution of treatment and management options transforming patient outcomes.
• Recognize misdiagnosed urticaria and implement testing options when patients are not responding to appropriate therapy.